Skip to main content Skip to section navigation Skip to footer
Lexaria Bioscience Corp.Lexaria BioscienceLexaria Bioscience
Lexaria Bioscience Corp.

NASDAQ:LEXX; NASDAQ WARRANT:LEXXW

  • Home
  • About
    • Management
    • Board of Directors
    • Advisors & Consultants
  • Technology
    • Overview
    • Commercial Applications
    • Research
    • Patent Portfolio
  • Licensing Opportunities
  • Investors
Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Presentations
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • 2022 Annual General Meeting
    • FAQ
  • Analyst Coverage
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Legend Removal
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Apr 14, 2022 8:45am EDT

Lexaria's Pulmonary Hypertension Clinical Study HYPER-H21-3 Delivers Positive Results

Apr 12, 2022 9:10am EDT

Lexaria Provides Update on Human Nicotine Study NIC-H22-1

Apr 11, 2022 9:00am EDT

Lexaria Begins New Nicotine Formulation Creation and Evaluation Program

Mar 15, 2022 2:05pm EDT

Lexaria Begins DehydraTECH-CBD Epilepsy Research Program

Mar 08, 2022 9:15am EST

Lexaria Granted Important New Oral Nicotine Patent

Feb 02, 2022 9:25am EST

Lexaria Reports Potentially Ground-Breaking Findings in Sildenafil Animal Study

Jan 27, 2022 9:35am EST

Lexaria Provides Annual Letter From the CEO

Jan 18, 2022 9:25am EST

Lexaria Comments on Study Examining Cannabinoids and SARS-CoV-2

Dec 29, 2021 11:15am EST

Lexaria Receives Independent Review Board Approval For DehydraTECH-CBD Human Clinical Study HYPER-H21-4

Dec 16, 2021 2:45pm EST

Lexaria Enters One-Year Media Outreach Agreement with SRAX, Inc.

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 18
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.

250.765.6424
info@lexariabioscience.com

Lexaria Bioscience Corp.
#100-740 McCurdy Road
Kelowna, BC, V1X2P7

Privacy Policy

General Disclaimer:
No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases…

Read More

Copyright ©2022 All rights reserved.

Back to the top